Pub Date : 2024-09-01DOI: 10.1016/j.remn.2024.500018
A. Padilla Bermejo, J. Gatón Ramírez, F.J. Pena Pardo, M. de las Nieves Sicilia Pozo, M. del Prado Talavera Rubio, V. Poblete García
{"title":"Resección incompleta en un raro caso de paraganglioma vesical evidenciado mediante 123I-MIBG SPECT/TC con diurético","authors":"A. Padilla Bermejo, J. Gatón Ramírez, F.J. Pena Pardo, M. de las Nieves Sicilia Pozo, M. del Prado Talavera Rubio, V. Poblete García","doi":"10.1016/j.remn.2024.500018","DOIUrl":"10.1016/j.remn.2024.500018","url":null,"abstract":"","PeriodicalId":48986,"journal":{"name":"Revista Espanola De Medicina Nuclear E Imagen Molecular","volume":"43 5","pages":"Article 500018"},"PeriodicalIF":1.6,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142168060","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
[18F]FDG PET/MRI (PET/MR-3.0 T, Signa.GE) whole body and heart was performed, baseline and 1 year post-ART.
Qualitative vascular assessment (hepatic reference). Quantitative assessment (SUVmax) of the whole body. T1 and T2 value estimation in 16 myocardial segments.
Results
Baseline CMR showed in 3 (21.4%) a decreased LVEF, normalising post-TAR. Fibrosis was ruled out (T1), with no signs of myocardial oedema (T2) at baseline or post-TAR.
Four (28.6%) showed baseline vascular [18F]FDG uptake, two in ascending thoracic aorta and two in ascending and descending thoracic aorta, normalising post-TAR.
All (100%) showed basal lymph-nodes activity; supra (n:14) and infradiaphragmatic (n:13), laterocervical (n:14) and inguinal (n:13), with variable number of territories (9 patients >6; 64.3%). Post-ART, 7 patients (50%) showed resolution and the other 7 reduction in extension (0 patients >5): 7 supra (100%) and 2 infradiaphragmatic (28.6%), 5 in the axilla and 2 in the groin.
All (100%) had persistent basal adenoid uptake post-ART, 9 (64.3%) splenic all resolved post-ART and 7 (50.5%) gastric, persistent 3 post-ART.
Conclusions
Cardiovascular biomarkers by [18F]FDG PET/MR have shown baseline 28.6% of patients with large vessel activity and 21.4% with low LVEF, normalising post-ART.
Inflammatory/immune biomarkers showed baseline activity in 100% of lymph-nodes, 100% adenoids, 64.3% splenic and 50.5% gastric. Post-TAR the reduction was 50% lymph-nodes, 0% adenoid, 100% splenic and 57.1% gastric.
{"title":"Asociación entre la inflamación cardiovascular y los cambios del sistema inmune inducidos por la infección por VIH mediante PET/RM con [18F]FDG","authors":"J.R. Garcia , R. Olivero , I. Arrieta-Aldea , J.A. Romero , E. Riera , E. Cañas-Ruano , N. Garrido , J. Du , R. Guerri","doi":"10.1016/j.remn.2024.500042","DOIUrl":"10.1016/j.remn.2024.500042","url":null,"abstract":"<div><h3>Objective</h3><p>To assess by [<sup>18</sup>F]FDG PET/MR the biomarkers of HIV-induced inflammation at baseline and 1 year post-antiretroviral therapy (ART).</p></div><div><h3>Methods</h3><p>Prospective study, 14 patients, newly diagnosed HIV-positive, asymptomatic.</p><p>[<sup>18</sup>F]FDG PET/MRI (PET/MR-3.0<!--> <!-->T, Signa.GE) whole body and heart was performed, baseline and 1 year post-ART.</p><p>Qualitative vascular assessment (hepatic reference). Quantitative assessment (SUVmax) of the whole body. T1 and T2 value estimation in 16 myocardial segments.</p></div><div><h3>Results</h3><p>Baseline CMR showed in 3 (21.4%) a decreased LVEF, normalising post-TAR. Fibrosis was ruled out (T1), with no signs of myocardial oedema (T2) at baseline or post-TAR.</p><p>Four (28.6%) showed baseline vascular [<sup>18</sup>F]FDG uptake, two in ascending thoracic aorta and two in ascending and descending thoracic aorta, normalising post-TAR.</p><p>All (100%) showed basal lymph-nodes activity; supra (n:14) and infradiaphragmatic (n:13), laterocervical (n:14) and inguinal (n:13), with variable number of territories (9 patients<!--> <!-->>6; 64.3%). Post-ART, 7 patients (50%) showed resolution and the other 7 reduction in extension (0 patients<!--> <!-->>5): 7 supra (100%) and 2 infradiaphragmatic (28.6%), 5 in the axilla and 2 in the groin.</p><p>All (100%) had persistent basal adenoid uptake post-ART, 9 (64.3%) splenic all resolved post-ART and 7 (50.5%) gastric, persistent 3 post-ART.</p></div><div><h3>Conclusions</h3><p>Cardiovascular biomarkers by [<sup>18</sup>F]FDG PET/MR have shown baseline 28.6% of patients with large vessel activity and 21.4% with low LVEF, normalising post-ART.</p><p>Inflammatory/immune biomarkers showed baseline activity in 100% of lymph-nodes, 100% adenoids, 64.3% splenic and 50.5% gastric. Post-TAR the reduction was 50% lymph-nodes, 0% adenoid, 100% splenic and 57.1% gastric.</p></div>","PeriodicalId":48986,"journal":{"name":"Revista Espanola De Medicina Nuclear E Imagen Molecular","volume":"43 5","pages":"Article 500042"},"PeriodicalIF":1.6,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142168702","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-07-01DOI: 10.1016/j.remn.2024.500017
This continuing education aims to present in a clear and easy-to-understand manner the biology of paragangliomas and pheochromocytomas (PPGLs), the functional imaging studies available for their diagnosis and therapeutic planning, the requirements necessary to administer radioligand therapy (RLT) and the characteristics of these treatments (inclusion criteria, administration protocols, adverse effects and future perspectives).
In this pathology we have two RLT options: [131I]MIBG and [177Lu]Lu-DOTA-TATE. The indication for treatment is determined by the expression of its therapeutic target in functional imaging studies, allowing precision and personalized medicine.
Although most of the results we have for both treatments have as origin small retrospective series, RLT is presented as a safe and well-tolerated therapeutic option in PPGLs with slow-moderate progression or with uncontrollable symptoms, obtaining high disease control rates.
{"title":"Radioteragnosis en paragangliomas y feocromocitomas","authors":"","doi":"10.1016/j.remn.2024.500017","DOIUrl":"10.1016/j.remn.2024.500017","url":null,"abstract":"<div><p>This continuing education aims to present in a clear and easy-to-understand manner the biology of paragangliomas and pheochromocytomas (PPGLs), the functional imaging studies available for their diagnosis and therapeutic planning, the requirements necessary to administer radioligand therapy (RLT) and the characteristics of these treatments (inclusion criteria, administration protocols, adverse effects and future perspectives).</p><p>In this pathology we have two RLT options: [<sup>131</sup>I]MIBG and [<sup>177</sup>Lu]Lu-DOTA-TATE. The indication for treatment is determined by the expression of its therapeutic target in functional imaging studies, allowing precision and personalized medicine.</p><p>Although most of the results we have for both treatments have as origin small retrospective series, RLT is presented as a safe and well-tolerated therapeutic option in PPGLs with slow-moderate progression or with uncontrollable symptoms, obtaining high disease control rates.</p></div>","PeriodicalId":48986,"journal":{"name":"Revista Espanola De Medicina Nuclear E Imagen Molecular","volume":"43 4","pages":"Article 500017"},"PeriodicalIF":1.6,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141405964","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-07-01DOI: 10.1016/j.remn.2024.500021
H. Şan , Ö. Bayrakçi , B. Çağdaş , M. Serdengeçti , E. Alagöz
<div><h3>Purpose</h3><p>Searching for online health information is a popular approach employed by patients to enhance their knowledge for their diseases. Recently developed AI chatbots are probably the easiest way in this regard. The purpose of the study is to analyze the reliability and readability of AI chatbot responses in terms of the most commonly applied radionuclide treatments in cancer patients.</p></div><div><h3>Methods</h3><p>Basic patient questions, thirty about RAI, PRRT and TARE treatments and twenty-nine about PSMA-TRT, were asked one by one to GPT-4 and Bard on January 2024. The reliability and readability of the responses were assessed by using DISCERN scale, Flesch Reading Ease(FRE) and Flesch-Kincaid Reading Grade Level(FKRGL).</p></div><div><h3>Results</h3><p>The mean (SD) FKRGL scores for the responses of GPT-4 and Google Bard about RAI, PSMA-TRT, PRRT and TARE treatments were 14.57 (1.19), 14.65 (1.38), 14.25 (1.10), 14.38 (1.2) and 11.49 (1.59), 12.42 (1.71), 11.35 (1.80), 13.01 (1.97), respectively. In terms of readability the FRKGL scores of the responses of GPT-4 and Google Bard about RAI, PSMA-TRT, PRRT and TARE treatments were above the general public reading grade level. The mean (SD) DISCERN scores assesses by nuclear medicine phsician for the responses of GPT-4 and Bard about RAI, PSMA-TRT, PRRT and TARE treatments were 47.86 (5.09), 48.48 (4.22), 46.76 (4.09), 48.33 (5.15) and 51.50 (5.64), 53.44 (5.42), 53 (6.36), 49.43 (5.32), respectively. Based on mean DISCERN scores, the reliability of the responses of GPT-4 and Google Bard about RAI, PSMA-TRT, PRRT, and TARE treatments ranged from fair to good. The inter-rater reliability correlation coefficient of DISCERN scores assessed by GPT-4, Bard and nuclear medicine physician for the responses of GPT-4 about RAI, PSMA-TRT, PRRT and TARE treatments were 0.512 (95% CI 0.296: 0.704), 0.695 (95% CI 0.518: 0.829), 0.687 (95% CI 0.511: 0.823) and 0.649 (95% CI 0.462: 0.798), respectively (<em>P</em><.01). The inter-rater reliability correlation coefficient of DISCERN scores assessed by GPT-4, Bard and nuclear medicine physician for the responses of Bard about RAI, PSMA-TRT, PRRT and TARE treatments were 0.753 (95% CI 0.602: 0.863), 0.812 (95% CI 0.686: 0.899), 0.804 (95% CI 0.677: 0.894) and 0.671 (95% CI 0.489: 0.812), respectively (<em>P</em><.01). The inter-rater reliability for the responses of Bard and GPT-4 about RAİ, PSMA-TRT, PRRT and TARE treatments were moderate to good. Further, consulting to the nuclear medicine physician was rarely emphasized both in GPT-4 and Google Bard and references were included in some responses of Google Bard, but there were no references in GPT-4.</p></div><div><h3>Conclusion</h3><p>Although the information provided by AI chatbots may be acceptable in medical terms, it can not be easy to read for the general public, which may prevent it from being understandable. Effective prompts using ‘prompt engineering’ may refine the responses
目的搜索在线健康信息是患者常用的一种方法,以增强他们对疾病的了解。最近开发的人工智能聊天机器人可能是这方面最简单的方法。本研究的目的是分析人工智能聊天机器人就癌症患者最常使用的放射性核素治疗方法所做回答的可靠性和可读性。方法在 2024 年 1 月向 GPT-4 和 Bard 逐一询问了患者的基本问题,其中 30 个是关于 RAI、PRRT 和 TARE 治疗的,29 个是关于 PSMA-TRT 的。采用 DISCERN 量表、Flesch Reading Ease(FRE)和 Flesch-Kincaid Reading Grade Level(FKRGL)对回答的可靠性和可读性进行了评估。结果 GPT-4 和 Google Bard 中关于 RAI、PSMA-TRT、PRRT 和 TARE 治疗的回答的 FKRGL 平均得分(标清)分别为 14.57(1.19)、14.65(1.38)、14.25(1.10)、14.38(1.2)和 11.49(1.59)、12.42(1.71)、11.35(1.80)、13.01(1.97)。就可读性而言,关于 RAI、PSMA-TRT、PRRT 和 TARE 治疗的 GPT-4 和 Google Bard 的 FRKGL 分数高于一般公众的阅读水平。核医学医生对 GPT-4 和谷歌巴德关于 RAI、PSMA-TRT、PRRT 和 TARE 治疗的回答进行评估后得出的 DISCERN 平均分(标度)分别为 47.86(5.09)、48.48(4.22)、46.76(4.09)、48.33(5.15)和 51.50(5.64)、53.44(5.42)、53(6.36)、49.43(5.32)。根据 DISCERN 平均得分,GPT-4 和 Google Bard 关于 RAI、PSMA-TRT、PRRT 和 TARE 治疗的回答的可靠性从一般到良好不等。由 GPT-4、谷歌巴德和核医学医生对 GPT-4 关于 RAI、PSMA-TRT、PRRT 和 TARE 治疗的回答所评估的 DISCERN 分数的评分者间可靠性相关系数为 0.512(95% CI 0.296:0.704)、0.695(95% CI 0.518:0.829)、0.687(95% CI 0.511:0.823)和 0.649(95% CI 0.462:0.798)(P<.01)。由 GPT-4、Bard 和核医学医生评估的 Bard 关于 RAI、PSMA-TRT、PRRT 和 TARE 治疗的 DISCERN 评分的评分者间可靠性相关系数分别为 0.753(95% CI 0.602:0.863)、0.812(95% CI 0.686:0.899)、0.804(95% CI 0.677:0.894)和 0.671(95% CI 0.489:0.812)(P<.01)。Bard和GPT-4对RAİ、PSMA-TRT、PRRT和TARE治疗的反应的评分者间可靠性为中等至良好。此外,GPT-4 和 Google Bard 很少强调向核医学医生咨询,Google Bard 的一些回答中包含了参考文献,但 GPT-4 中没有参考文献。使用 "提示工程 "进行有效提示可能会以更易于理解的方式完善回复。由于放射性核素治疗是核医学专业知识的特定内容,因此需要在回答中说明核医学医生是顾问,以指导患者和护理人员获得准确的医疗建议。就患者和护理人员寻求信息的信心和满意度而言,参考意义重大。
{"title":"Análisis de confiabilidad y lectibilidad de ChatGPT-4 y Google Gard como fuente de información del paciente para los tratamientos con radionúclidos más comúnmente aplicados en pacientes con cáncer","authors":"H. Şan , Ö. Bayrakçi , B. Çağdaş , M. Serdengeçti , E. Alagöz","doi":"10.1016/j.remn.2024.500021","DOIUrl":"10.1016/j.remn.2024.500021","url":null,"abstract":"<div><h3>Purpose</h3><p>Searching for online health information is a popular approach employed by patients to enhance their knowledge for their diseases. Recently developed AI chatbots are probably the easiest way in this regard. The purpose of the study is to analyze the reliability and readability of AI chatbot responses in terms of the most commonly applied radionuclide treatments in cancer patients.</p></div><div><h3>Methods</h3><p>Basic patient questions, thirty about RAI, PRRT and TARE treatments and twenty-nine about PSMA-TRT, were asked one by one to GPT-4 and Bard on January 2024. The reliability and readability of the responses were assessed by using DISCERN scale, Flesch Reading Ease(FRE) and Flesch-Kincaid Reading Grade Level(FKRGL).</p></div><div><h3>Results</h3><p>The mean (SD) FKRGL scores for the responses of GPT-4 and Google Bard about RAI, PSMA-TRT, PRRT and TARE treatments were 14.57 (1.19), 14.65 (1.38), 14.25 (1.10), 14.38 (1.2) and 11.49 (1.59), 12.42 (1.71), 11.35 (1.80), 13.01 (1.97), respectively. In terms of readability the FRKGL scores of the responses of GPT-4 and Google Bard about RAI, PSMA-TRT, PRRT and TARE treatments were above the general public reading grade level. The mean (SD) DISCERN scores assesses by nuclear medicine phsician for the responses of GPT-4 and Bard about RAI, PSMA-TRT, PRRT and TARE treatments were 47.86 (5.09), 48.48 (4.22), 46.76 (4.09), 48.33 (5.15) and 51.50 (5.64), 53.44 (5.42), 53 (6.36), 49.43 (5.32), respectively. Based on mean DISCERN scores, the reliability of the responses of GPT-4 and Google Bard about RAI, PSMA-TRT, PRRT, and TARE treatments ranged from fair to good. The inter-rater reliability correlation coefficient of DISCERN scores assessed by GPT-4, Bard and nuclear medicine physician for the responses of GPT-4 about RAI, PSMA-TRT, PRRT and TARE treatments were 0.512 (95% CI 0.296: 0.704), 0.695 (95% CI 0.518: 0.829), 0.687 (95% CI 0.511: 0.823) and 0.649 (95% CI 0.462: 0.798), respectively (<em>P</em><.01). The inter-rater reliability correlation coefficient of DISCERN scores assessed by GPT-4, Bard and nuclear medicine physician for the responses of Bard about RAI, PSMA-TRT, PRRT and TARE treatments were 0.753 (95% CI 0.602: 0.863), 0.812 (95% CI 0.686: 0.899), 0.804 (95% CI 0.677: 0.894) and 0.671 (95% CI 0.489: 0.812), respectively (<em>P</em><.01). The inter-rater reliability for the responses of Bard and GPT-4 about RAİ, PSMA-TRT, PRRT and TARE treatments were moderate to good. Further, consulting to the nuclear medicine physician was rarely emphasized both in GPT-4 and Google Bard and references were included in some responses of Google Bard, but there were no references in GPT-4.</p></div><div><h3>Conclusion</h3><p>Although the information provided by AI chatbots may be acceptable in medical terms, it can not be easy to read for the general public, which may prevent it from being understandable. Effective prompts using ‘prompt engineering’ may refine the responses","PeriodicalId":48986,"journal":{"name":"Revista Espanola De Medicina Nuclear E Imagen Molecular","volume":"43 4","pages":"Article 500021"},"PeriodicalIF":1.6,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141839048","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-07-01DOI: 10.1016/j.remn.2024.500020
F.J. de Haro del Moral , S. Aguadé Bruix , M.J. Tabuenca Mateo , M.P. Tamayo Alonso , L. Mohamed Salem , L. Bernal , D. Primiano , P. Tarilonte
Aim
Myocardial uptake on bone scintigraphy has become useful for the detection of transthyretin cardiac amyloidosis (ATTR-CA). This study aimed to assess the prevalence of myocardial uptake in patients over 18 years of age with no clinical suspicion of cardiac amyloidosis (CA) who had undergone bone scintigraphy.
Methods and results
This was an observational, retrospective, multicenter study across 21 Spanish hospitals (September–November 2019). Of the 9864 scans analyzed (locally and centrally), incidental cardiac uptake was observed in 71 patients (0.72%), a prevalence that increased with age. A previous diagnosis of heart failure was found in 16.9% of patients with positive uptake, with >50% in NYHA II. ATTR-CA was diagnosed in 10 patients, with a mean delay of 10.4 months (95% CI: 5.1-15.7). All were >70 years old, primarily male, and had greater left ventricular hypertrophy than patients without a confirmed diagnosis (p< 0.0001). ATTR-CA patients had higher rates of orthostatic hypotension (30.0% vs. 3.8% in non-ATTR-CA; p = 0.025).
Conclusions
This is the first retrospective, national, multicenter study evaluating the prevalence of incidental cardiac uptake in bone scintigraphy performed for non-cardiac reasons, showing a prevalence of 0.72% in this population. Referral of these patients may facilitate early diagnosis of CA with a resulting benefit for patients.
目的 骨闪烁成像的心肌摄取已成为检测转甲状腺素心脏淀粉样变性(ATTR-CA)的有用方法。本研究旨在评估接受骨闪烁成像检查的 18 岁以上、临床上未怀疑患有心脏淀粉样变性(CA)的患者的心肌摄取率。方法和结果这是一项观察性、回顾性、多中心研究,涉及 21 家西班牙医院(2019 年 9 月至 11 月)。在分析的9864例扫描(局部和中央)中,71例患者(0.72%)观察到偶发性心脏摄取,其发生率随年龄增长而增加。16.9%的摄取阳性患者曾被诊断为心力衰竭,其中50%为NYHA II。10名患者确诊为ATTR-CA,平均延迟时间为10.4个月(95% CI:5.1-15.7)。与未确诊的患者相比,所有患者均为>70岁,主要为男性,左心室肥厚程度更高(p< 0.0001)。ATTR-CA患者的正张性低血压发生率较高(30.0% vs. 3.8% in non-ATTR-CA;p = 0.025)。结论这是第一项回顾性、全国性、多中心研究,评估了因非心脏原因进行骨闪烁扫描时意外摄取心脏信号的发生率,结果显示该人群的发生率为 0.72%。转诊这些患者可促进 CA 的早期诊断,从而使患者受益。
{"title":"Evaluación de la captación cardiaca incidental en la gammagrafía ósea en España: el estudio ECCINGO","authors":"F.J. de Haro del Moral , S. Aguadé Bruix , M.J. Tabuenca Mateo , M.P. Tamayo Alonso , L. Mohamed Salem , L. Bernal , D. Primiano , P. Tarilonte","doi":"10.1016/j.remn.2024.500020","DOIUrl":"10.1016/j.remn.2024.500020","url":null,"abstract":"<div><h3>Aim</h3><p>Myocardial uptake on bone scintigraphy has become useful for the detection of transthyretin cardiac amyloidosis (ATTR-CA). This study aimed to assess the prevalence of myocardial uptake in patients over 18 years of age with no clinical suspicion of cardiac amyloidosis (CA) who had undergone bone scintigraphy.</p></div><div><h3>Methods and results</h3><p>This was an observational, retrospective, multicenter study across 21 Spanish hospitals (September–November 2019). Of the 9864 scans analyzed (locally and centrally), incidental cardiac uptake was observed in 71 patients (0.72%), a prevalence that increased with age. A previous diagnosis of heart failure was found in 16.9% of patients with positive uptake, with<!--> <!-->>50% in NYHA II. ATTR-CA was diagnosed in 10 patients, with a mean delay of 10.4 months (95% CI: 5.1-15.7). All were<!--> <!-->>70 years old, primarily male, and had greater left ventricular hypertrophy than patients without a confirmed diagnosis (<em>p</em><<!--> <!-->0.0001). ATTR-CA patients had higher rates of orthostatic hypotension (30.0% vs. 3.8% in non-ATTR-CA; p<!--> <!-->=<!--> <!-->0.025).</p></div><div><h3>Conclusions</h3><p>This is the first retrospective, national, multicenter study evaluating the prevalence of incidental cardiac uptake in bone scintigraphy performed for non-cardiac reasons, showing a prevalence of 0.72% in this population. Referral of these patients may facilitate early diagnosis of CA with a resulting benefit for patients.</p></div>","PeriodicalId":48986,"journal":{"name":"Revista Espanola De Medicina Nuclear E Imagen Molecular","volume":"43 4","pages":"Article 500020"},"PeriodicalIF":1.6,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2253654X24000283/pdfft?md5=9b700d264c6d0de207d3419e4e63f693&pid=1-s2.0-S2253654X24000283-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141951740","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-07-01DOI: 10.1016/j.remn.2024.500026
M. Negre , S. Agramunt , N. Ferran , P. Paredes
In recent years, concern about the effects of ionizing radiation on exposed individuals has led to the need to regulate and quantify the use of diagnostic and therapeutic techniques. Geopolitical events in recent times have also increased the population's perception of insecurity regarding ionizing radiation, and we increasingly face patients reluctant to undergo certain types of scans in our nuclear medicine services and, albeit less frequently, in radiology services. This article aims to summarise the extent to which ionizing radiation is present in our daily lives and how diagnostic and therapeutic procedures can affect our health, particularly from the perspective of their effects on the thyroid gland, one of the body's most radiation-sensitive organs.
{"title":"Actualización sobre la protección radiológica de la glándula tiroides","authors":"M. Negre , S. Agramunt , N. Ferran , P. Paredes","doi":"10.1016/j.remn.2024.500026","DOIUrl":"10.1016/j.remn.2024.500026","url":null,"abstract":"<div><p>In recent years, concern about the effects of ionizing radiation on exposed individuals has led to the need to regulate and quantify the use of diagnostic and therapeutic techniques. Geopolitical events in recent times have also increased the population's perception of insecurity regarding ionizing radiation, and we increasingly face patients reluctant to undergo certain types of scans in our nuclear medicine services and, albeit less frequently, in radiology services. This article aims to summarise the extent to which ionizing radiation is present in our daily lives and how diagnostic and therapeutic procedures can affect our health, particularly from the perspective of their effects on the thyroid gland, one of the body's most radiation-sensitive organs.</p></div>","PeriodicalId":48986,"journal":{"name":"Revista Espanola De Medicina Nuclear E Imagen Molecular","volume":"43 4","pages":"Article 500026"},"PeriodicalIF":1.6,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141951754","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-07-01DOI: 10.1016/j.remn.2024.500024
A. García-Ruiz, I. Martínez-Rodríguez, N. Martínez-Amador, N.V. Carvalho-Duarte, J. Jiménez-Bonilla, R. Quirce
{"title":"Identificación de ganglio centinela axilar no detectado en cáncer de mama tratado con quimioterapia neoadyuvante","authors":"A. García-Ruiz, I. Martínez-Rodríguez, N. Martínez-Amador, N.V. Carvalho-Duarte, J. Jiménez-Bonilla, R. Quirce","doi":"10.1016/j.remn.2024.500024","DOIUrl":"10.1016/j.remn.2024.500024","url":null,"abstract":"","PeriodicalId":48986,"journal":{"name":"Revista Espanola De Medicina Nuclear E Imagen Molecular","volume":"43 4","pages":"Article 500024"},"PeriodicalIF":1.6,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141951757","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-07-01DOI: 10.1016/j.remn.2024.500036
J.R. Garcia, R. Jover, M. Mila, A. Muxi, V. Vallejos, A. Garcia, E. Caballero
{"title":"Descifrando el futuro: desafíos y oportunidades de la medicina nuclear","authors":"J.R. Garcia, R. Jover, M. Mila, A. Muxi, V. Vallejos, A. Garcia, E. Caballero","doi":"10.1016/j.remn.2024.500036","DOIUrl":"10.1016/j.remn.2024.500036","url":null,"abstract":"","PeriodicalId":48986,"journal":{"name":"Revista Espanola De Medicina Nuclear E Imagen Molecular","volume":"43 4","pages":"Article 500036"},"PeriodicalIF":1.6,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141843606","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}